Hikal posts FY23 PAT at Rs. 36 Cr
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Open, scalable, end-to-end solution to improve diagnostic quality and efficiency
Time to combine innovation, access and technology to deliver positive patient outcomes
Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Subscribe To Our Newsletter & Stay Updated